D
uring the past decade in Canada, there has been a rap id and re lentless increase in antimicrobia l resistance in Streptococcus pneumoniae and Haemophi/us irifluenzae.
These two bacteria l pathogens are frequently associated with resp iratory tract infections, incl uding community-acquired pneumonia (CAP), in both chil dren and adul ts (1,2). The consequences of infections due to resista nt strains incl ude the likelihood of inappropriate initial therapy, the need to sometimes use less effective alternative antimicrobia ls and increased heal thcare costs. Because clinicia ns are usually un-aware of the pathogen or its antimicrobial susceptibility when initially deciding on the therapy, it is important to know the rates of resistance in the community and the consequences of using an antimicrobial to which the offending organism is resistant. Such knowledge will help physicians decide when it is appropriate to change empirical therapy.
DETERMINING THE CONSEQUENCES OF ANTIMICROBIAL RESISTANCE
It is often difficult to measure the effect of inappropriate treatment of an infection with an antibiotic to which the offending organism is resistant. There are a number of clinical infectious syndromes for which the benefit of antimicrobial therapy is questionable. Criteria that determine the resistance of an organism to a particular antimicrobial or group of antimicrobials may not always correlate with treatment outcomes. Finally, comorbid illnesses or physiological processes are often not accounted for when attempting to determine whether treatment failure is due to antimicrobial resistance.
Infections that are caused by organisms that are resistant to the antimicrobial used may appear to respond because the natural history of the infection is often to resolve spontaneously. Examples include acute sinusitis and mild to moderate acute exacerbation of chronic bronchitis (3) (4) (5) (6) . van Buchem et al (4) randomly assigned patients that had been diagnosed as having acute maxillary sinusitis to placebo or amoxicillin. They found that amoxicillin did not influence the clinical course or the frequency of relapses. Anthonisen et al (3) found that antibiotics were ineffective in mild acute exacerbations of chronic bronchitis. They did, however, find a difference in the success rate between antibiotic and placebo for the more severe exacerbations; deterioration in patients with more severe exacerbations was over twice as common with placebo as with antibiotic. The benefit of antimicrobial therapy has been clearly established for bacterial pneumonia (7) . In the preantibiotic era, over 80% of CAP was due to S pneumoniae, with mortality rates of20% to 40% (7, 8) . In the antibiotic era, the overall mortality rates of CAP are less than 6% and for S pneumoniae are less than 15% (9, 10) . However, there is also evidence to suggest that the mortality of bacteremic pneumococcal pneumonia has not changed over the past several decades, even with additional therapeutical and supportive measures, including intensive care unit support (11, I 2).
The clinical relevance of resistance in vitro may depend on the site of infection and the degree of resistance. What constitutes resistance of an organism to an antibiotic in vitro may not be relevant for the site at which the organism is causing the infection. Penicillin therapy is frequently ineffective in meningitis caused by pneumococci exhibiting intermediate resistance because of the relatively low concentrations of penicillin achievable in the cerebrospinal fluid. However, there is no convincing evidence that therapy with penicillin or an equally active beta-lactam antibiotic is ineffective in pneumonia or bacteremia due to pneumococci that are intermediately or highly resistant to penicillin (13) .
Finally, when trying to assess the relationship between anCan J Infect Dis Vol 9 Suppl E November/December 1998 ti biotic activity and outcome, several factors have to be taken into consideration including the type of pathogen, the physiological response by the host and underlying comorbid illnesses. Mortality is closely associated with the etiology of the infection. Patients with Pseudomonas aeruginosa. Staphylococcus aureus and enteric Gram-negative rod pneumonia (eg, Klebsiella species and Escherichia coli) have overall mortalities of greater than 30% (9). Austrian and Gold (7) found that the mortality rate for type I pneumococcal bacteremia was 8% for all cases, whereas that for type III infection was 55%. Despite the benefit seen with the use of antibiotics for the treatment of S pneumoniae bacteremia, the mortality in the first five days of the illness has not been altered (7) . Austrian and Gold (7) found that the percentage of patients who had died with bacteremic pneumococcal pneumonia was similar for those patients that were untreated, or treated with penicillin, tetracycline or serum therapy during the first five days of the diagnosis of their illness. In addition, 60% of all deaths among patients treated with penicillin were found to occur in the first five-day period, despite treatment often being initiated on the first or second day of the illness. This suggests that factors in addition to the pathogen , such as the physiological response by the host, are important regarding outcome. Factors that are independently associated with mortality include the following: age older than 50 years. neoplastic disease, congestive heart failure, cerebrovascular disease, renal disease and liver disease (10) . Despite these obse1vations, there are important inte1ven -tions that can be made that improve the outcome of the patient with CAP. Leroy et al (14) identified 16 predictors of mortality for severe CAP. Among the factors found in the multivariate analysis, three were found to be attributable Lo medical interventions: the use of antimicrobial combinations (protective effect); delayed initiation of mechanical ventilation (greater than 12 h) ; and ineffective antimicrobial therapy, as defined by failure of clinical improvement and decrease in fever at 72 h of treatment. These findings underscore the need not only to provide coverage for all potential etiologies but also to be aware of local resistance rates to ensure the choice of the most effective antimicrobial.
WHEN ANTIMICROBIAL RESISTANCE MAY BE RELEVANT
When considering the relevance of antimicrobial resistance of the bacterial pathogens that are etiological agents of CAP, it is important to consider whether the agent causes a concomitant bacteremia and the level of resistance of the organism to the antimicrobial. Although H i,J!!uenzae is often cited as one of the most frequent causes of CAP, it is infrequently isolated from the blood (15). In studies carried out before the introduction of the H irlfluenzae type b vaccine, approximately one-third to one-half of the blood culture-documented cases of H irlfluenzae pneumonia were caused by type b ( 16, l 7). To date in Canada, due to the widespread use of the type b vaccine, the rate of colonization and invasive disease, such as pneumonia and bacteremia, is significantly less in all age groups (18). s pneumoniae is clearly the most important bacterial pathogen causing CAP. Approximately 30% of all cases of CAP due to 
BETA-LACTAMS
Beta-lactams kill S pneumoniae by binding to the penicillinbinding proteins (PBPs) , thereby preventing the bacteria from making new cell wall. Resistance in S pneumoniae is due entirely to the development of low affinity PBPs and not to the production of a beta-lactamase as is resistance in H irlfluenzae (19). Penicillin-susceptible S pnewnoniae contain six PBPs. In isolates that have a high level resistance to penicillin , there have been reductions in the affinities of at least three of the PBPs. High level resistance to cephalosporins requires reductions in the affinities of only two PBPs (20) . Penicillin resistance in S pneumoniae is subdivided according to the minimal inhibitory concentration (MIC) of the organism. Pneumococci for which the MIC of penicillin is less than 0.1 mg/Lare defined as susceptible, those for which the MIC is 0.1 to 1.0 mg/L as intermediately resistant, and those for which the MIC is greater than 1.0 mg/Las highly resistant (Table 1) (21). Currently, the rates of intermediately and highly resistant strains of S pneumoniae in Canada are greater than 14% (Figure 1) .
The use of the oral beta-lactams for the treatment of penicillin-resistant, nonmeningeal invasive pneumococcal in- Figure 2 ) Th e evolution qfbeta-lactamase-positive Haemophilus influenzae in Canada. AdaptedJ rom references 28, [62] [63] [64] [65] fections is controversial ( 13, (22) (23) (24) . The MIC breakpoint above which penicillin therapy is likely to be ineffective for non meningeal infections is unknown but is probably 4.0 mg/L or greater. Such strains are rare in North America (25, 26) . Beta-lactam resistance in H irifluenz ae is due almost exclusively to the acquisition and expression of the TEM and ROB beta -lactamase genes (27) . The rates of beta-lactamasepositive H irlfluenzae are greater than 40% (Figure 2) (27 ,28) . The percentage of beta-lactamase-negative, amoxicillinresistantH irlfluenz ae, presumably with PBP modifications, is less than 2% (27) . The relevance of this increase in resistance to the impact of the treatment of CAP is questionable. In addition, second-and third-generation cephalosporins have retained excellent activity against the beta-lactamase-positive strains in Canada (27, 28) .
MACROLIDES
Macrolides (erythromycin, clarithromycin and azithromycin) inhibit protein synthesis by binding to the SOS ribosomal subunits and inhibit elongation of peptide chains. Macrolide resistance in S pneumoniae is due primarily to the acquisition of a gene that is responsible for either efflux of the macrolide out of the cell or a gene that is responsible for modifying the ribosome so as to prevent attachment. Susceptibility is defined as an MIC less than 0.5 mg/L (Table 1 ). The mean M!Cs for strains resistant due to efflux is 10 mg/Land for those strains resistant due to ribosomal modification is 64 mg/L (29) . Peak levels in serum from 2 to 3 mg/L, from 0.5 to 1 mg/Land 0.4 mg/Lare reached at 3 h after oral doses of erythromycin (500 mg), clarithromycin (250 mg) and azithromycin (500 mg), respectively (30) . Therefore, the development of resistance is a several-fold increase in the MIC above achievable concentrations in the serum, a finding that may be quite relevant for bacteremia (31, 32) . However, it may be less relevant for pneumonia because concentrations of macrolides in the intrapulmonary epithelial-lining fluid and alveolar macrophages are 10-to 100-fold higher than that in serum (33) (34) (35) (36) .
FLUOROQUINOLONES
The target for the fluoroquinolones is the topoisomerases. Topoisomerases are enzymes in bacteria that are responsible for DNA coiling. There are four topoisomerases, two of which However, other fluoroquinolones with excellent activity against the respiratory pathogens, including S pneumoniae, have recently become available or will soon be. These fluoroquinolones include levofloxacin, sparfloxacin , gatifloxacin , grepafloxacin, trovafloxacin , clinafloxacin and moxifloxacin . The National Committee for Clinical Laboratory Standards (Villanova, Pennsylvania) (2 l) has recently provided MIC interpretive standards for S pneumoniae Jor levofloxacin, sparfloxacin, grepafloxacin and trovafloxacin (Table l) . These compounds are very potent against isolates of S pneumoniae (MICgo less than 0.5 ~tg/L). including isolates that are resistant to penicillin and macrolides (Table 2) of CAP, including pneumonia due to S pneumoniae (44 -50) .
When resistance develops, the efficacy of these newer quinolones may be compromised (4 I) . However, as with the macrolides, the fluoroquinolones achieve higher concentrations in the alveolar macrophages and the epithelial-lining fluid than in the serum (51 -53) . This may provide effective concentrations, even though an isolate is resistant in vitro. The ability of fluoroquinolones to concentrate in lung tissue may explain why the reports of failure of ciprofloxacin for the treatment of pneumococcal pneumonia have been so rare, where it has been used either advertently or inadvertently (42.54 -57) .
TRIMETHOPRIM/SULFAMETHOXAZOLE
Soon after the introduction of rrimethoprim/sulfamethoxazole (TMP/SMX) in the late l 960s , the first isolate of TMP/SMX-resistant S pneumoniae was cultured. Since, resistance has steadily increased and is strongly associated with penicillin resistance (Table 3) (58) . A variety of mechanisms of resistance have been identified. The most frequently encountered mechanism is the production of an additional dihydrofolJE Low late reductase enzyme that prevents the reduction of dihydrofolate Lo tetrahydrofolate and is less sens i tive than the chromosomal enzyme to inhibition by trimethoprim. Trimethoprim resistance is strongly associated with TMP/SMX resistance in S pneumoniae (59) . Strains of S pneumoniae that are resistant to TMP/SMX by this mechanism have M!Cs (64 mg/Lor greater) that are well above the breakpoints for resistance and concentrations achievable in the serum or lung tissue (Table L) (60) . S pneumoniae has been shown to be only moderately susceptible to trimethoprim, and it has been suggested that infections caused by this organism require the synergy induced by the sulfamethoxazole in the TMP/SMX combination for effective therapy (61) . In the lung tissues , in a guinea pig model , not only are the concentrations of trimethoprim below the MIC of the resistant strain, but there is also a differential deposition of trimethoprim and sulfamethoxazole (60) . In bronchoa lveo lar lavage flu id and alveolar macrophages, trimethoprim concentration is 10 times higher than sulphamethoxazole concentration. In view of the high rates of resistance (greater than 18%) and the pharmacokinetics ofTMP/SMX , it may be unwise to recommend it as an alternative regimen in the treatment of CAP.
PREVALEN CE OF ANTIMICROBIAL RESISTAN CE TO
RESPIRATORY PATHOGENS IN CANADA During the past decade, there has been a marked increase in beta -lactamase-med iated amoxici ll in resistance in H irJ!luenzae (Figure 2 ). Since the late 1980s, beta-lactamase resistance in H irJ!luenzae has increased from 15% to greater than 43% (28, (62) (63) (64) (65) . Similar increases in penicillin-resistant S pneumoniae have occurred (Figure 1) . However, the concomitant increase in resistance to other classes of antibiotics has been of more concern (Table 3, Figure I ). This results in decreased activity of all antibiotics to S pneumoniae, with the exception of the new fluoroquinolones (Table 2) .
CONCLUSION
The emergence of resistance poses a serious threat to the health of Canadians. Reducing the inappropriate use antimicrobials is of the utmost importance. Numerous studies have found that physicians routinely prescribe antibiotics for clinical syndromes in which antimicrobials are known to have no effect (5, 6) . Physicians overprescribe antibiotics because of patient expectations, insufficient time to discuss with patients why an antib iotic is not needed, and concern that they may misdiagnose bacterial infections where an antibiotic is indicated (66) . Therefore, there is an urgent need both to improve prescribing practices and to provide the tools for physicians to diagnosis more accurately those conditions for which an antibiotic is indicated (66, 67) . National programs in Iceland and Finland have demonstrated that programs to curtail antibiotic use can result in both decreased antibiotic use and antimicrobial resistance (68, 69) . Similar programs are urgently needed in Canada, othe1wise resistance will continue to progress to current first-and second-line antibiotics, and possibly to the newer fluoroquinolones. Clinical studies are required to determine the impact of resistance on the outcome of therapy.
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